abstract: UNASSIGNED: Purpose To assess whether @entity0 molecular subtype classified by surrogate markers can be used to predict the extent of clinically relevant disease with preoperative breast magnetic resonance (MR) imaging. Materials and Methods In this HIPAA-compliant, institutional review board-approved study, informed consent was waived. Preoperative breast MR imaging reports from 441 @entity1 were reviewed for @entity66 , lymph node involvement, skin and/or nipple invasion, chest wall and/or pectoralis muscle invasion, or @entity66 . Pathologic reports were reviewed to confirm the MR imaging findings and for hormone receptors (estrogen and progesterone subtypes), @entity1 epidermal growth factor receptor type 2 ( @entity1722 subtype), @entity5 size, and @entity5 grade. Surrogates were used to categorize @entity5 by molecular subtype: hormone receptor positive and @entity1722 negative (luminal A subtype); hormone receptor positive and @entity1722 positive (luminal B subtype); hormone receptor negative and @entity1722 positive ( @entity1722 subtype); hormone receptor negative and @entity1722 negative (basal subtype). All @entity1 included in the study had a histologic correlation with MR imaging findings or they were excluded.   (2) analysis was used to compare differences between subtypes, with multivariate logistic regression analysis used to assess for variable independence. Results Identified were 289 (65.5%) luminal A, 45 (10.2%) luminal B, 26 (5.9%) @entity1722 , and 81 (18.4%) basal subtypes. Among subtypes, significant differences were found in the frequency of @entity66 (luminal A, 27.3% [79 of 289]; luminal B, 53.3% [24 of 45]; @entity1722 , 65.4% [17 of 26]; basal, 27.2% [22 of 81]; P < .001) and lymph node involvement (luminal A, 17.3% [50 of 289]; luminal B, 35.6% [26 of 45]; @entity1722 , 34.6% [nine of 26]; basal 24.7% [20 of 81]; P = .014). Multivariate analysis showed that molecular subtype was independently predictive of multifocal and/or @entity66 . Conclusion Preoperative breast MR imaging is significantly more likely to help detect multifocal and/or @entity66 and lymph node involvement in luminal B and @entity1722 molecular subtype @entity0 . Molecular subtype may help to select @entity1 for preoperative breast MR imaging.    RSNA, 2014.

title: Can @entity0 Molecular Subtype Help to Select XXXX for Preoperative MR Imaging?

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['multicentric and/or multifocal disease', 'multicentric disease', 'contralateral disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: UNASSIGNED: Treatment of @entity1 with drug-eluting stent (DES) in-stent restenosis (ISR) is particularly challenging. We sought to compare results of @entity661 in @entity1 with DES-ISR with those in @entity1 with bare-metal stent (BMS) ISR. A pooled analysis of the @entity256 Intra-Stent: Drug-Eluting Balloon versus @entity2239 -Eluting Stent IV and V randomized trials was performed. Both trials had identical inclusion and exclusion criteria. Results of @entity661 in 95 @entity1 with BMS-ISR and 154 @entity1 with DES-ISR were compared. @entity1 with DES-ISR were more frequently diabetics, presented more often as an @entity1187 and had more severe lesions and more frequently a focal pattern, including edge-ISR. Late angiographic findings (92% of eligible @entity1 ), including minimal lumen diameter (1.80    0.6 vs 2.01     0.6  mm, p  = 0.001; absolute mean difference 0.21  mm; 95% confidence interval 0.04 to 0.38; p  = 0.014) and restenosis rate (19% vs 9.5%, p <0.05) were poorer in DES-ISR. Results were consistent across 10 prespecified subgroups. Moreover, on multiple linear regression analysis, minimal lumen diameter at follow-up remained significantly smaller in @entity1 with DES-ISR after adjusting for potential confounders (adjusted absolute mean difference 0.17  mm; 95% confidence interval 0.04 to 0.41; p  = 0.019). Finally, at 1-year clinical follow-up (100% of @entity1 ), rates of target vessel revascularization (16% vs 6%, p  = 0.02) and of the main combined clinical end point (18% vs 8%, p  = 0.03) were significantly higher in @entity1 treated for DES-ISR. In conclusion, this study confirms the efficacy of @entity16905 for @entity1 with ISR. However, the long-term clinical and angiographic results of DEB are poorer in @entity1 with DES-ISR than in those with BMS-ISR. (ClinicalTrials.govIdentifier:NCT01239953_NCT01239940).

title: Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent XXXX (from the RIBS IV and V Randomized Trials).

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndrome']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['Restenosis']

entities_list: @entity2239 :: ('MESH:C107135', 'Chemical') :: ['Everolimus']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['drug-eluting balloons']

answer: @entity256 :: (MESH:D023903,Disease) :: ['Restenosis']


abstract: Disturbances of skin barrier function occur in several @entity272 , e.g., @entity483 ( @entity483 ), @entity9759 ( @entity9759 , @entity13685 ). Skin barrier damage triggers the production of cytokines that stimulate lipogenesis which may also cause inflammatory processes. The aim of this study was to evaluate the efficacy of a topical skin lipid mixture in the treatment of @entity9759 , @entity13685 and @entity483 . 580 consecutive @entity1 suffering from @entity9759 , @entity13685 or @entity483 were treated with a skin lipid mixture containing @entity2367 -3 and patented nanoparticles. @entity1 received the lipid mixture alone or in combination with topical corticosteroids until clearance or for 8 weeks. Both treatment groups statistically improved all parameters considered at week 4 and 8 as compared to baseline. Between the 2 treatment groups, there was a statistically significant difference @entity34 ( @entity9759 , @entity13685 , @entity483 , respectively): @entity5105 , @entity111 and overall disease severity; @entity5105 and @entity111 ; @entity5105 , @entity111 , fissuring and overall disease severity. No statistically significant difference was found for ( @entity9759 , @entity13685 , @entity483 , respectively): dryness, scaling and fissuring; scaling, fissuring and overall disease severity; dryness and scaling. Between the 2 @entity13685 treatment groups, there was a statistically significant difference in favour of the skin lipid mixture for dryness. In conclusion, the study shows that balanced lipid mixtures are effective in improving barrier properties and the clinical condition of the skin in contact @entity1909 .

title: Evaluation of efficacy of a skin lipid mixture in @entity1 with XXXX , allergic contact dermatitis or @entity483 : a multicenter study.

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis', 'AD']

entities_list: @entity9759 :: ('MESH:D017453', 'Disease') :: ['ICD', 'irritant/allergic contact dermatitis']

entities_list: @entity111 :: ('MESH:D011537', 'Disease') :: ['pruritus']

entities_list: @entity2367 :: ('CHEBI:17761', 'Chemical') :: ['ceramide']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin diseases']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['in favour of combined therapy for']

answer: @entity9759 :: (MESH:D017453,Disease) :: ['irritant contact dermatitis']


abstract: AIMS: @entity842 (NO) in peripheral venous blood has been shown to be elevated in experimental @entity101 . This study aims to determine the serum NO levels in @entity1 with extrahepatic @entity101 (EHPVO) pre- and postoperatively and to analyze whether these can serve as a reliable and early indicator of shunt blockage or malfunction. MATERIALS AND METHODS: During the period 2006-2010, 48 @entity1 with EHPVO were included in this prospective study; 40 underwent porto-systemic shunt and eight underwent splenectomy with devascularization. NO was evaluated preoperatively, 14 days after surgery, at 3 months and then 6 monthly thereafter. The median follow-up duration was 21 months. Shunt patency was confirmed with Doppler and computed tomography portography. Forty-eight age-matched @entity1 with @entity2650 served as controls. RESULTS: NO was higher in EHPVO @entity1 as compared with controls (43.16    16.27 vs. 5.76    2.62  mol/l) (P = 0.0001). There was a significant decline in the NO levels (4.64    3.18  mol/l) following shunt surgery (P = 0.0001), and it continued to remain low till the shunt was patent. A shunt block was indicated by rising NO levels in all five @entity1 . The devascularization group also demonstrated a significant decline in the NO levels (27.06    3.56  mol/l) (P = 0.002), but it was less as compared with the shunted @entity1 . The decline in the portal pressure after shunt surgery was found to correlate with the decline in the serum NO levels. CONCLUSIONS: The blood levels of NO can be used in the diagnosis of @entity101 , and are useful for monitoring the patency of the shunt.

title: The role of @entity842 in XXXX caused by extrahepatic portal vein obstruction.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['portal venous hypertension', 'portal hypertension']

entities_list: @entity2650 :: ('MESH:D007021', 'Disease') :: ['hypospadias']

answer: @entity101 :: (MESH:D006973,Disease) :: ['portal hypertension']


abstract: The purpose of this study is to define the importance of age as predictor of early and late mortality following @entity583 ( @entity583 ). At the same time, effects coming from the use of various therapeutic approaches are considered. We have studied 341 @entity1 , 188 aged < 70 years and 153 > or = 70 years, consecutively admitted to the coronary care unit with diagnosis of @entity583 . Our findings show that age > or = 70 years, female gender, @entity1455 , @entity2224 and early post- @entity1188 angina are significantly connected to higher intra-hospital mortality. As for predictors of 1-year mortality, they turned out to be the age > or = 70 years, indirect signs of more extensive @entity1188 as previous @entity39 , @entity712 , @entity1455 , new @entity5036 and pre-discharging lower ventricular ejection fraction. In @entity1 aged > or = 70 years, especially in ultra eighty-year old @entity1 , thrombolysis, heparin, beta-blockers and @entity117 are significantly less employed. All drugs used in the early hours of @entity583 turned out to be bound to beneficial effects with reduced mortality, except diuretics and antiarrhythmics. The only drugs correlated with an improved 1 year survival are betablockers, @entity117 and thrombolysis. On the contrary, the use of diuretics and digoxin is limited to @entity1 with a greater clinical dysfunction. These drugs are associated to a higher late mortality. The present study confirms the finding that elderly @entity1 with @entity583 who are submitted to less aggressive therapeutic approaches and are more frequently represented by @entity1 , have a higher mortality.

title: [The effect of age on early and late mortality after an acute XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['acute heart failure']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin']

entities_list: @entity5036 :: ('OMIM:113900', 'Disease') :: ['bundle branch blocks']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction']

entities_list: @entity2224 :: ('MESH:D014693', 'Disease') :: ['ventricular fibrillation']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['AMI', 'acute myocardial infarction']

entities_list: @entity1455 :: ('MESH:D012770', 'Disease') :: ['cardiogenic shock']

answer: @entity583 :: (MESH:D009203,Disease) :: ['myocardial infarct']


abstract: OBJECTIVES: This study sought to assess the presence and extent of inducible @entity296 during @entity158 and painless (silent) @entity741 in a homogeneous @entity1 cohort with @entity453 and no previous @entity583 . BACKGROUND: The functional significance of painless versus @entity158 remains controversial, with conflicting results in published reports regarding the amount of myocardium in jeopardy. METHODS: Exercise echocardiography was performed in 89 @entity1 (mean [+/- SD] age 59.3 +/- 8.2 years) with significant @entity453 and positive exercise stress test results. @entity1 were taking no antianginal medications and were classified into painless and @entity158 cohorts after the outcome of a symptom-limited treadmill exercise test. No @entity1 had previous coronary artery bypass surgery. Images were acquired in digital format before and immediately after treadmill exercise testing. RESULTS: Fifty-eight @entity1 had @entity158 and 31 painless @entity741 . Clinical and demographic characteristics as well as coronary artery anatomy were similar in both groups. @entity1 with @entity63 achieved better exercise performance with greater exercise duration (p < 0.001) and higher maximal rate-blood pressure product (p < 0.001) than those with @entity158 @entity63 . New wall motion abnormalities were seen in 54 @entity1 (93%) with @entity158 (55%) with @entity63 (p < 0.001). Total @entity63 score was greater in @entity1 with @entity158 than in those with @entity63 (15.9 +/- 3.7 vs. 12 +/- 1.4, p < 0.001, respectively), with a greater number of @entity63 @entity296 in @entity158 than in @entity63 (101 [16%] vs. 21 [6%], p < 0.001, respectively). CONCLUSIONS: @entity1 with @entity63 frequently have regional @entity296 on exertion detected by echocardiography, but @entity158 episodes are accompanied by a greater magnitude of @entity296 .

title: Magnitude of XXXX is greater in @entity158 than in painless @entity741 : an exercise echocardiographic study.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial segments', 'myocardial dysfunction']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['painless ischemia', 'ischemia', 'ischemic']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful versus 17', 'painful demand-driven ischemia', 'painful']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

answer: @entity296 :: (MESH:D009202,Disease) :: ['myocardial dysfunction']


abstract: UNASSIGNED: Some clusters of severe @entity221 with @entity882 (SFTSV) @entity281 were reported in China as of 2010. However, to date, there has been no epidemiologic evidence of aerosol transmission of SFTSV. Epidemiologic investigations were conducted after a cluster of 13 cases of SFTSV in May 2014. A total of 13 cases, including 11 confirmed cases and one clinically diagnosed case, were identified besides the case of the index @entity1 . The index @entity1 experienced onset of SFTSV on 23 April and died on 1 May. The @entity1 with secondary cases had onset from 10 to 16 May, peaking on 13 May. Moreover, eight secondary cases occurred in family members of the index @entity1 , and the other five cases occurred in neighbors of the index @entity1 . According to epidemiologic investigations, @entity1 1, 3, 4, 5, 6, 7, 9 and 12 contracted the disease through contact with blood of the index @entity1 . Notably, @entity1 8 and 10 did not have a history of contact with the blood of the index @entity1 , but they stayed in the mourning hall for hours. SFTSV could be transmitted from @entity1 to @entity1 by direct contact and/or aerosol transmission, and it is important to consider aerosol transmission as a possible transmission route.

title: Probable aerosol transmission of severe @entity221 with XXXX in southeastern China.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia syndrome virus']

answer: @entity882 :: (MESH:D013921,Disease) :: ['thrombocytopenia syndrome virus']


abstract: BACKGROUND: This study aimed to determine the relationship between @entity4166 mRNA copy number in sentinel lymph nodes (SLN) assessed by one-step nucleic acid amplification (OSNA) technique, and non-sentinel lymph nodes (NSLN) metastization in @entity0 . A model using total @entity5 load (TTL) obtained by OSNA technique was also constructed to evaluate its predictability. METHODS: We conducted an observational retrospective study including 598 @entity1 with clinically T1-T3 and node negative @entity0 . Of the 88 @entity1 with positive SLN, 58 @entity1 fulfill the inclusion criteria. RESULTS: In the analyzed group 25.86% had at least one positive NSLN in axillary lymph node dissection. Univariate analysis showed that @entity5 size, TTL and number of SLN macrometastases were predictive factors for NSLN @entity3 . In multivariate analysis just the TTL was predictive for positive NSLN (OR 2.67; 95% CI 1.06-6.70; P  =  0.036). The ROC curve for the model using TTL alone was obtained and an AUC of 0.805 (95% CI 0.69-0.92) was achieved. For TTL >1.9  *  10(5) copies/ L we got 73.3% sensitivity, 74.4% specificity and 88.9% negative predictive value to predict NSLN @entity3 . CONCLUSION: When using OSNA technique to evaluate SLN, NSLN @entity3 can be predicted intraoperatively. This prediction tool could help in decision for axillary lymph node dissection.

title: Total @entity5 load assessed by one-step nucleic acid amplification assay as an intraoperative predictor for non-sentinel lymph node XXXX in @entity0 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['invasive breast cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastasis']


abstract: We report a case of @entity9933 with @entity825 , which shows unique histological findings. A 1056 g male @entity1 was delivered by cesarean section for fetal @entity1763 at 28 wk of gestation. Immediately after birth, he had frequent apneic spells and required intubation and ventilation for 70 days. After he was discharged at 240 days of age, he had occasional apneic spells and was resuscitated by his family doctor. When he was admitted to our hospital at 11 months of age, he had a respiratory rate of 32 breaths/min with retractions, and auscultation revealed biphasic wheezes. Chest X-ray and bronchoscope examination showed a stenotic and malacic section of the upper @entity825 . When he was 1 year and 2 months old, an operation was performed. The diseased portion was resected and end-to-end @entity254 with interrupted absorbable suture was performed. The postoperative course was uneventful and he was discharged from our hospital on the 46th postoperative day. Histologically, the @entity705 was composed of some islets of cartilage. Furthermore, there were some striated muscle cells on the inside of the incomplete @entity705 . To our knowledge, this finding has never been reported in earlier papers. We suppose that some of the visceral mesenchymal tissue which should form the esophagus became sequestered in the tracheal region before the esophageal and tracheal tubes completely separated.

title: [A case of @entity9933 with XXXX due to esophageal remnants].

entities_list: @entity825 :: ('MESH:D055090', 'Disease') :: ['tracheomalacia', 'trachea']

entities_list: @entity705 :: ('MESH:D015831', 'Disease') :: ['cartilaginous ring']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity9933 :: ('MESH:C536975', 'Disease') :: ['congenital tracheal stenosis']

answer: @entity825 :: (MESH:D055090,Disease) :: ['tracheomalacia']


abstract: AIM: @entity1252 ( @entity1252 ) is the most common @entity792 associated with pregnancy. The aim of this study was to evaluate management and outcome of pregnancy complicated by @entity1252 . METHODS: Twenty pregnant @entity1 affected by @entity1252 were admitted to Prenatal Diagnosis Centre of University "Sapienza" from January 2007 to July 2009. Pregnancy was monitored from diagnosis to delivery by at least a monthly consultation. At each visit general blood laboratory assessment were registered. An ultrasound examination was performed to evaluate fetal growth. From 26 weeks of gestation an estimation of fetal weight was calculated according to the standard of Lubchenco. At birth newborns weight was registered. RESULTS: @entity1 mean age was 32.9 years. There were 18 live births (90%), and 2 spontaneous abortions; 50% of pregnancy ended with a @entity3152 . 20% of the @entity1 had signs of disease activity during pregnancy. Fifteen percent of @entity1 presented @entity101 . An high rate of small for gestational age was registered and 2 cases of @entity1592 ( @entity1592 ). Ultrasound evaluation at 28-30 weeks of gestation showed a normal weight (>=  50th percentile) in 83% fetuses. Only 45% of the newborns presented >=  50th percentile. The mean weight of the newborns was 2700 grams. CONCLUSION: Pregnancy outcome could be improved by close obstetrical and ultrasound monitoring in a multidisciplinary setting.

title: [Pregnancy in lupus XXXX : our experience].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient', 'Patient']

entities_list: @entity3152 :: ('MESH:D007752', 'Disease') :: ['preterm delivery']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['gestational hypertension']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['Systematic lupus erythematosus', 'SLE']

entities_list: @entity1592 :: ('MESH:D005317', 'Disease') :: ['IUGR', 'intrauterine growth retardation']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The AS04-adjuvanted @entity1082 ) 16/18 vaccine ( @entity13921  ) is a noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that induce a strong immunogenic response eliciting high levels of anti-L1 VLP antibodies that persist at levels markedly greater than those observed with @entity281 . The vaccine adjuvant (AS04) is composed of @entity13922 , which enhances cellular and humoral immune response, adsorbed to @entity13923 . The vaccine is indicated for the prevention of @entity75 and @entity5 causally related to certain oncogenic HPV types in females aged >= 10 years. The AS04-adjuvanted @entity1799 /18 vaccine, administered via an intramuscular injection in a three-dose schedule over 6 months, elicits a high immunogenic response and is highly protective against @entity3146 and @entity281 causally related to high-risk oncogenic HPV types. In well designed clinical trials in young @entity1 aged 15-25 years who were @entity1799 /18 seronegative and DNA negative to 14 HPV high-risk types, high levels of immunogenicity and protection were sustained for follow-up periods of up to 8.4 years. High and persistent immunogenicity against @entity281 with @entity1799 /18 has also been demonstrated in older and younger females (aged 10-55 years) who were seronegative for vaccine HPV types. The AS04-adjuvanted @entity1799 /18 vaccine elicited a greater immunogenic response than the quadrivalent HPV vaccine in @entity1 aged 18-45 years who were seronegative and DNA negative for @entity1799 /18. The AS04-adjuvanted @entity1799 /18 vaccine confers cross protection against certain non-vaccine, high-risk HPV types. A rapid and strong anamnestic humoral immune response was elicited following a fourth dose of the vaccine. The AS04-adjuvanted @entity1799 /18 vaccine is generally well tolerated, and pharmacoeconomic analyses have demonstrated the potential for public health benefits and cost effectiveness when vaccination programs are run in conjunction with screening programs. Thus, the AS04-adjuvanted @entity1799 /18 vaccine prevents @entity3799 associated with certain oncogenic HPV types, thereby reducing the burden of @entity75 and, very likely, @entity5 .

title: Spotlight on AS04-adjuvanted @entity1082 ) types 16 and 18 vaccine ( XXXX  ).

entities_list: @entity13923 :: ('MESH:D000536', 'Chemical') :: ['aluminum hydroxide']

entities_list: @entity13922 :: ('MESH:C048436', 'Chemical') :: ['monophosphoryl-lipid A']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['premalignant cervical lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['natural infection', 'infection']

entities_list: @entity3799 :: ('MESH:D002575', 'Disease') :: ['cervical disease']

entities_list: @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['cervical intraepithelial neoplasia']

answer: @entity13921 :: (MESH:C510352,Chemical) :: ['Cervarix']


abstract: BACKGROUND: Within work sociology, several studies have addressed construction workers' practices of masculinity, class, economy, safety risks and production. However, few studies have investigated room for agency in relation to @entity158 or @entity85 and even fewer have made a quantitative approach. Accordingly, by means of a questionnaire, we examined the association between construction workers' room for agency and physical exertion, bodily and @entity615 . METHODS: A total of 481 Danish construction workers who responded to a multifaceted questionnaire were included. Drawing on previous studies and a Foucauldian inspired concept of agency, agency was quantified through specially crafted questions and examined in relation to established measures on physical exertion, physical and mental @entity1295 and @entity158 in the lower back. Associations were tested using analyses of variance (general linear models) and controlled for age, gender, job group, lifestyle and @entity308 . RESULTS: When asked about options for agency reducing the burden of work, few workers believed themselves to be prime agents of such practices. When asking about their view on performing alternative agency implying caring for the body, 39-49% expected negative reactions from management, and 20-33% expected negative reactions from colleagues. In contrast, only 13-18% of the @entity1 stated that they would give a negative reception to such alternative practices. Using the expected reception outcomes (positive, neutral, negative) to alternative practices as predictors, the statistical regression analyses showed that negative expectations to management were associated with higher levels of physical exertion 0.62 (95% CI   =   0.14-1.09) (scale 0-11), bodily @entity1295 0.63 (95% CI   =   0.22-1.04), mental @entity1295 0.60 (95% CI   =   0.07-1.12), and @entity1643 0.79 (95% CI   =   0.13-1.46) (scales 0-10). CONCLUSION: In our study, construction workers answered questions about work and @entity11159 . The answers indicated a contradiction between perceived responsibility and room for agency. Based on the study, a number of target areas could fruitfully be addressed in aiming to reduce @entity11159 among construction workers. To change workers' expectances to the reception of lowering work pace if needed to take care of the body, their expectances to the reception of sickness absence as a result of @entity158 , of discussing physical exertion in work and of demanding appropriate technical assistive devices are such examples. Our results emphasize that management plays an important role in this.

title: Contradictory individualized self-blaming: a cross-sectional study of associations between expectations to managers, coworkers, one-self and risk factors for XXXX among construction workers.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity1643 :: ('MESH:D017116', 'Disease') :: ['low back pain']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['mental fatigue, and lower back pain']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'bodily pain']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['musculoskeletal disorders']

answer: @entity85 :: (MESH:D009140,Disease) :: ['musculoskeletal disorders']


abstract: INTRODUCTION: To identify independent predictors of radiographic progression in @entity5144 ( @entity5144 ) for @entity1 treated with adalimumab or placebo in the Adalimumab Effectiveness in @entity5144 Trial (ADEPT). METHODS: Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression (change in modified total Sharp score, DeltamTSS>0.5) from baseline to week 24 for @entity1851 ( @entity1851 ) and other baseline variables, and for 24-week time-averaged @entity1851 (univariate analysis only). Subanalyses determined mean DeltamTSS for @entity1851 subgroups. Analyses were post hoc, with observed data. RESULTS: One hundred and forty-four adalimumab-treated @entity1 and 152 placebo-treated @entity1 were assessed. Mean @entity1851 was 64% lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated @entity1851 at baseline and time-averaged @entity1851 were strongly associated with radiographic progression for placebo-treated @entity1 but not for adalimumab-treated @entity1 . Multivariate analysis confirmed that elevated baseline @entity1851 was the only strong independent risk factor for radiographic progression (for @entity1851 >or=1.0 mg/dl: odds ratio=3.28, 95% confidence interval=1.66 to 6.51, P<0.001). Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean DeltamTSS for adalimumab versus placebo was greatest for @entity1 with baseline @entity1851 >or=2.0 mg/dl (-0.5 vs. 2.6). CONCLUSIONS: Systemic @entity32 in @entity5144 , as indicated by elevated baseline @entity1851 , was the only strong independent predictor of radiographic progression. This association was observed predominantly for placebo-treated @entity1 . Adalimumab treatment substantially reduced the overall risk of radiographic progression, and provided greatest radiographic benefit for @entity1 with the greatest @entity1851 concentrations at baseline. TRIAL REGISTRATION: Trial registration: NCT00195689.

title: Risk factors for radiographic progression in XXXX : subanalysis of the randomized controlled trial ADEPT.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['PsA', 'psoriatic arthritis']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity5144 :: (MESH:D015535,Disease) :: ['psoriatic arthritis']


abstract: AIM: @entity7057 ( @entity7057 ) is a potentially life-threatening @entity66 with high mortality. In case of a massive @entity1410 , surgical drainage is a crucial treatment. The aim of the present study was to assess the efficacy of the endoscope-assisted keyhole technique in elderly @entity1 with @entity1779 who needed a flap craniotomy as traditional treatment. MATERIAL AND METHODS: One hundred-eighty-four elderly @entity1 with @entity7057 , who had craniotomy indications after conservative treatment for 6-24 hours after onset, were randomly divided into two groups. In the craniotomy group, traditional @entity1410 drainage was performed. In the keyhole group, an endoscope-assisted keyhole technique was used. Anesthesia time, @entity190 , @entity1410 drainage rate, and complications were compared. The clinical primary outcome was the six-month efficacy rate (defined by the activities of daily living (ADL) score). RESULTS: Anesthesia time was longer in the craniotomy group (3.43  0.65 vs. 1.53  0.52 h, P < 0.01), and blood losses were more important (256  129 vs. 96  39 ml P < 0.01). There was no difference in @entity1410 drainage rate between the two groups (77.25  13.44 vs. 83.52  27.51% P > 0.05). Complications, including tracheotomy (P < 0.01), @entity358 (P < 0.01) and @entity9427 (P < 0.05) were more frequent in the craniotomy group. There was no difference in the occurrence of other complications, including revision surgery digestive tract @entity1066 and @entity302 . Proportion of @entity1 with good prognosis (ADL I-III) was larger in the keyhole group (P < 0.05). CONCLUSION: In elderly @entity7057 @entity1 with an indication for @entity1410 drainage, better outcomes were achieved using an endoscope-assisted keyhole technique.

title: Endoscope-Assisted Keyhole Technique for @entity7057 in Elderly @entity1 : A Randomized Controlled Study in 184 XXXX .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular disease']

entities_list: @entity7057 :: ('MESH:D020299', 'Disease') :: ['Hypertensive cerebral hemorrhage', 'HCH']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary infection']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity9427 :: ('MESH:D007019', 'Disease') :: ['hypoproteinemia']

entities_list: @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hematoma']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: OBJECTIVES: The purpose of this study was to assess the potential of late positive functional remodeling after percutaneous @entity338 (PPVI) in right ventricular outflow tract dysfunction. BACKGROUND: PPVI has been shown to impact acutely on biventricular function and exercise performance, but the potential for further late functional remodeling remains unknown. METHODS: Sixty-five @entity1 with sustained hemodynamic effects of PPVI at 1 year were included. @entity1 were divided into 2 subgroups based on pre-procedural predominant @entity849 ( @entity849 ) (n = 35) or predominant @entity338 ( @entity338 ) (n = 30). Data from magnetic resonance imaging and cardiopulmonary exercise testing were compared at 3 time points: before PPVI, within 1 month (early) and at 12 months (late) after PPVI. RESULTS: There was a significant decrease in right ventricle end-diastolic volume early after PPVI in both subgroups of @entity1 . Right ventricle ejection fraction improved early only in the @entity849 group (51    11% vs. 58    11% and 51    12% vs. 50    11%, p < 0.001 for @entity849 , p = 0.13 for @entity338 ). Late after intervention, there were no further changes in magnetic resonance parameters in either group (right ventricle ejection fraction, 58    11% in the @entity849 group and 52    11% in the @entity338 group, p = 1.00 and p = 0.13, respectively). In the @entity849 group at cardiopulmonary exercise testing, there was a significant improvement in peak @entity26 uptake early (24    8 ml/kg/min vs. 27    9 ml/kg/min, p = 0.008), with no further significant change late (27    9 ml/kg/min, p = 1.00). In the @entity338 group, no significant changes in peak @entity26 uptake from early to late could be demonstrated (25    8 ml/kg/min vs. 25    8 ml/kg/min vs. 26    9 ml/kg/min, p = 0.48). CONCLUSIONS: In @entity1 with a sustained hemodynamic result 1 year after PPVI, a prolonged phase of maintained cardiac function is observed. However, there is no evidence for further positive functional remodeling beyond the acute effects of PPVI.

title: Early versus late functional outcome after successful percutaneous XXXX : are the acute effects of altered right ventricular loading all we can expect?

entities_list: @entity338 :: ('MESH:D011665', 'Disease') :: ['pulmonary regurgitation', 'pulmonary valve implantation', 'PR']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity849 :: ('MESH:D011666', 'Disease') :: ['pulmonary stenosis', 'PS']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

answer: @entity338 :: (MESH:D011665,Disease) :: ['pulmonary valve implantation']


abstract: BACKGROUND: Vascular endothelial growth factor receptor @entity4149 kinase inhibitors ( @entity319 -TKIs) have been widely used in a variety of solid @entity5 . Concerns have arisen regarding the risk of severe @entity281 (>= grade 3) with use of these drugs, but the contribution of @entity319 -TKIs to @entity281 is still unknown. METHODS: The databases of PubMed and abstracts presented at oncology conferences' proceedings were searched for relevant studies from January 2000 to December 2014. Summary incidences, Peto odds ratio (Peto OR), and 95% confidence intervals (CIs) were calculated by using either random-effects or fixed-effects models according to the heterogeneity of included studies. RESULTS: A total of 16,488 @entity1 from 27 randomized controlled trials were included. The risk of developing severe (Peto OR 1.69, 95% CI: 1.45-1.96, P<0.001) and fatal @entity281 (Peto OR 1.78, 95% CI: 1.13-2.81, P=0.013) was significantly increased in @entity1 treated with @entity319 -TKIs when compared to controls. Exploratory subgroup analysis showed no effect of @entity5 types, phase of trials, or agent used on the Peto OR of severe @entity281 . When stratified according to specific infectious events, the risks of high-grade febrile @entity1398 , @entity55 , @entity221 , and @entity295 were increased compared with controls, with Peto ORs of 1.57 (95% CI: 1.30-1.88, P<0.001), 1.79 (95% CI: 1.29-2.49, P<0.001), 5.35 (95% CI: 1.47-19.51, P=0.011), and 3.68 (95% CI: 1.51-8.99, P=0.004), respectively. Additionally, @entity319 -TKIs significantly increased the risk of @entity295 (OR 3.66, 95% CI: 1.47-9.13, P=0.005) but not fatal @entity55 (OR 1.34, 95% CI: 0.80-2.25, P=0.26). CONCLUSION: The use of @entity319 -TKIs significantly increases the risk of developing severe and fatal infectious events in @entity5 @entity1 . A close monitoring for any signs of @entity281 is recommended for @entity1 treated with @entity319 -TKIs.

title: Increased risk of severe @entity281 in XXXX @entity1 treated with vascular endothelial growth factor receptor @entity4149 kinase inhibitors: a meta-analysis.

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis', 'fatal sepsis']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'malignancies']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: In response to stress and nutrient starvation, the @entity375 transcription factor @entity23763 accumulates in the nucleus and activates expression of a broad array of genes. Here, we analyze the role of the Tor (target of @entity3446 ) signaling pathway in mediating these responses. Inactivation of the Tor pathway component @entity23764 using @entity23764 (Ts) alleles causes a sustained nuclear localization similar to that after the addition of the Tor kinase inhibitor @entity3446 . Effects of @entity23764 inactivation and @entity3446 addition could be suppressed by deletion of TIP41, which encodes a @entity23764 -interacting protein. These results support the notion that @entity3446 affects @entity23763 by inactivating @entity23764 function. @entity23764 interacts with the catalytic subunit of PP2A (protein phosphatase 2A) and PP2A-like phosphatases. Deletion of either the catalytic or regulatory subunit that forms the PP2A phosphatase complex prevents nuclear accumulation of @entity23763 in the @entity23764 (Ts) strain and in wild-type strains treated with @entity3446 . These results suggest that @entity23764 is an inhibitor of PP2A phosphatase, which in turn inhibits nuclear export of @entity23763 . Interestingly, PP2A function is also required for nuclear accumulation of @entity23763 in response to stresses, such as heat and @entity1457 , as well as @entity1568 (but not @entity413 ) starvation. Thus, PP2A and the Tor kinase pathway transduce stress and @entity1568 starvation signals to @entity23763 . Finally, @entity23763 localization is unaffected by conditional loss of 14-3-3 protein function, ruling out the possibility that 14-3-3 proteins act as a scaffold to sequester @entity23763 in the cytoplasm.

title: PP2A phosphatase activity is required for stress and Tor kinase regulation of @entity375 stress response factor XXXX .

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity1457 :: ('MESH:D012769', 'Disease') :: ['osmotic shock']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['rapamycin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity375 :: ('4932', 'Species') :: ['Saccharomyces cerevisiae']

answer: @entity23763 :: (855053(Tax:4932),Gene) :: ['Msn2p']


abstract: Fifty-five @entity1 with malignant @entity694 were reviewed, and the CT findings were analyzed, as well as two cases of @entity5 of the terminal ileum. There is increased incidence of recurrence in @entity1 under 60 years of age, and 22% of local recurrences occurred 5 years or later after "curative" surgery. A local recurrence alone was found in 44% of @entity1 , distant metastases alone in 10%, and concomitant local recurrence and distant spread in 46%. Three-quarters of the locally recurrent masses were infiltrative and one-quarter were non-infiltrative. The important infiltrative elements included @entity79 , and 45% of those with @entity1494 had distant metastases. The finding of @entity3041 was associated with the presence of a local recurrence mass in all instances, and half of these cases had regional @entity3329 with @entity2617 . Furthermore, 60% of @entity1 demonstrating @entity3041 had distant metastases. The most commonly involved organs in distant metastatic spread were the liver and lungs There was a higher incidence of @entity3329 associated with pulmonary metastases than with hepatic deposits, which could possibly indicate different routes of spread. CT was found to be particularly helpful in detecting clinically occult recurrent disease. In clinically apparent disease, CT was able to assess the extent of the disease process and it also played a role in the practical therapeutic management of @entity1 .

title: The value of CT in malignant XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3329 :: ('MESH:D008206', 'Disease') :: ['lymphadenopathy']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['bladder infiltration']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['carcinoid tumors']

entities_list: @entity2617 :: ('MESH:D017254', 'Disease') :: ['local infiltration']

entities_list: @entity3041 :: ('MESH:D006869', 'Disease') :: ['hydronephrosis']

entities_list: @entity79 :: ('MESH:D001847', 'Disease') :: ['bone erosion']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic tumors']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colonic tumors']


abstract: The authors report the results of 782 microvascular decompression procedures for hemifacial @entity2473 in 703 @entity1 (705 sides), with follow-up study from 1 to 20 years (mean 8 years). Of 648 @entity1 who had not undergone prior intracranial procedures for hemifacial @entity2473 , 65% were @entity1 ; their mean age was 52 years, and the mean preoperative duration of symptoms was 7 years. The onset of symptoms was typical in 92% and atypical in 8%. An additional 57 @entity1 who had undergone prior microvascular decompression elsewhere were analyzed as a separate group. @entity1 were followed prospectively with annual questionnaires. Kaplan-Meier methods showed that among @entity1 without prior microvascular decompression elsewhere, 84% had excellent results and 7% had partial success 10 years postoperatively. Subgroup analyses (Cox proportional hazards model) showed that @entity1 had better results than @entity1 , and @entity1 with typical onset of symptoms had better results than those with atypical onset. Nearly all failures occurred within 24 months of operation; 9% of @entity1 underwent reoperation for recurrent symptoms. Second microvascular decompression procedures were less successful, whether the first procedure was performed at Presbyterian-University Hospital or elsewhere, unless the procedure was performed within 30 days after the first microvascular decompression. @entity1 age, side and preoperative duration of symptoms, history of @entity4401 , preoperative presence of @entity425 or @entity4402 , and implant material used had no influence on postoperative results. Complications after the first microvascular decompression for hemifacial @entity2473 included ipsilateral deaf ear in 2.6% and ipsilateral permanent, severe @entity425 in 0.9% of @entity1 . Complications were more frequent in reoperated @entity1 . In all, one operative death (0.1%) and two @entity1188 (0.3%) occurred. Microvascular decompression is a safe and definitive treatment for hemifacial @entity2473 with proven long-term efficacy.

title: Microvascular decompression for hemifacial XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'Patient', 'men']

entities_list: @entity4401 :: ('MESH:D020330', 'Disease') :: ["Bell's palsy"]

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['facial weakness']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['brainstem infarctions']

entities_list: @entity4402 :: ('MESH:D046608', 'Disease') :: ['synkinesis']

answer: @entity2473 :: (MESH:D013035,Disease) :: ['spasm']


abstract: In a review of 1248 cases of @entity31 seen at the Cleveland Clinic that were followed up to 1984 (mean, 14.4 years), 82 @entity1 (6.5%) were subsequently found to have @entity14 and 48 (3.8%) had @entity5 , 6 of them with associated @entity14 . Most @entity1 with @entity14 were @entity1 (2:1), and had extensive (90%) and long-lasting @entity1960 (10 years or more in 93% of cases; mean 18 years). @entity1960 was inactive before the diagnosis of @entity5 in 48%. Acute onset of the first attack was rare (7%), and the disease had a remittent course in 92%. The mean age at diagnosis of @entity5 was 43 years. The cumulative risk of @entity14 was significantly higher in @entity1 with extensive @entity1960 than in those with left-sided disease (P less than 0.0001: 11.9% vs. 1.8% at 20 years and 25.3% vs. 3.7% at 30 years). When comparing mean duration of disease, @entity1960 (22 years) did not differ significantly from @entity66 . The @entity5 was multifocal in 13.5%, proximal to the @entity4558 in 44%, and poorly differentiated in 34% of the cases. The diagnosis was suspected clinically in 64% of cases. The prognosis of @entity14 in @entity1 with @entity31 appears to be similar to that in the general population. The cumulative 5-year survival rate was 54%. This study supports the concept that surveillance colonoscopy should be started after 8 to 10 years of extensive @entity1960 and after 15 years of @entity1960 . Among those with @entity5 , the incidence of @entity1126 , @entity1778 , @entity3478 , and @entity1204 was significantly greater than expected (P less than 0.01), whereas that of @entity2 was significantly lower than expected (P less than 0.01).

title: XXXX in @entity31 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['extensive disease']

entities_list: @entity3478 :: ('MESH:D001859', 'Disease') :: ['bone tumors']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'extracolonic malignancy']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity4558 :: ('MESH:D013158', 'Disease') :: ['splenic flexure']

entities_list: @entity1126 :: ('MESH:D001650', 'Disease') :: ['bile duct carcinoma']

entities_list: @entity1960 :: ('MESH:D003092', 'Disease') :: ['left-sided colitis', 'colitis', 'Colitis']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['Colorectal and extracolonic malignancy']


abstract: BACKGROUND: @entity308 are highly prevalent in primary care (PC) and are associated with considerable functional impairment and increased health care use. Research has shown that many @entity1 prefer psychological treatments to pharmacotherapy, however, it remains unclear which treatment is most optimal for @entity308 @entity1 in primary care. METHODS/DESIGN: A randomized, multi-centre trial involving two intervention groups: one receiving brief cognitive behavioral therapy and the other receiving general practitioner care. General practitioners from 109 General Practices in Nijmegen and Amsterdam (The Netherlands) will be asked to include @entity1 aged between 18-70 years presenting with @entity308 symptomatology, who do not receive an active treatment for their @entity308 complaints. @entity1 will be telephonically assessed with the Structured Clinical Interview for DSM-IV @entity74 ( @entity915 -I) to ascertain study eligibility. Eligible @entity1 will be randomized to one of two treatment conditions: either 8 sessions of cognitive behavioral therapy by a first line psychologist or general practitioner's care according to The Dutch College of General Practitioners Practice Guideline (NHG- standard). Baseline and follow-up assessments are scheduled at 0, 6, 12 and 52 weeks following the start of the intervention. Primary outcome will be measured with the Hamilton Depression Rating Scale-17 (HDRS-17) and the @entity1 Health Questionnaire-9 (PHQ-9). Outcomes will be analyzed on an intention to treat basis. TRIAL REGISTRATION: ISRCTN65811640.

title: Brief cognitive behavioral therapy compared to general practitioners care for XXXX in primary care: a randomized trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['Depressive disorders', 'depressive']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Axis I Disorders']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: The neural inhibition of the gastrointestinal (GI) smooth muscle motility was studied by means of electrical transmural nerve stimulation (ETNS) in @entity840 . In untreated muscle strips, ETNS induced four types of response, consisting of three basic components, i.e., contraction and relaxation during ETNS, and after-contraction. Following atropinization, all the responses changed to only one type, i.e., relaxation during ETNS followed by after-contraction. The relaxation of the muscle strips induced by ETNS after atropinization was not significantly reduced under superimposing @entity2997 treatment in any site of the GI tract. The maximal relaxation of the muscle strips induced by ETNS after @entity3897 and @entity2997 treatments was not uniform throughout the GI tract. The relaxation of the gastric body and colon was greater than that of the jejunum and ileum. The extent of the relaxation was significantly different even in the colon. @entity2544 and @entity5521 did not reduce the ETNS-induced relaxation following @entity3897 and @entity2997 treatments in the distal colon and taenia coli. The findings suggest the following: the non-adrenergic inhibitory (NAI) nerve is the main postganglionic nerve to inhibit the GI smooth muscle motility; and the role of adrenergic nerve is of little importance in respect to postganglionic inhibition. The innervation of the NAI nerve seems not to be uniform throughout the GI tract. Theophylline and @entity5521 are not the specific antagonists of the NAI nerve.

title: Neural inhibition of gastrointestinal smooth muscle motility in XXXX .

entities_list: @entity2997 :: ('MESH:D006145', 'Chemical') :: ['guanethidine']

entities_list: @entity2544 :: ('MESH:D013806', 'Chemical') :: ['Theophylline']

entities_list: @entity5521 :: ('MESH:D010646', 'Chemical') :: ['phentolamine']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['atropine']

answer: @entity840 :: (10141,Species) :: ['guinea-pigs']


abstract: Despite suggestions that higher serum @entity1760 ( @entity4612 ) levels are associated with improved outcome, the association with mortality in European hemodialysis (HD) @entity1 has only scarcely been investigated. Furthermore, data on the association between serum @entity4612 and @entity944 in this @entity1 group is limited. Therefore, we evaluated @entity4612 in a post-hoc analysis using pooled data from the CONvective TRAnsport STudy (CONTRAST, NCT00205556), a randomized controlled trial (RCT) evaluating the survival risk in dialysis @entity1 on hemodiafiltration (HDF) compared to HD with a mean follow-up of 3.1 years. Serum @entity4612 was measured at baseline and 6, 12, 24 and 36 months thereafter. Cox proportional hazards models, adjusted for confounders using inverse probability weighting, were used to estimate hazard ratios (HRs) of baseline serum @entity4612 on all-cause mortality, @entity65 , non- @entity65 and @entity944 . A generalized linear mixed model was used to investigate @entity4612 levels over time. Out of 714 randomized @entity1 , a representative subset of 365 (51%) were analyzed in the present study. For every increase in baseline serum @entity4612 of 0.1 mmol/L, the HR for all-cause mortality was 0.85 (95% CI 0.77-94), the HR for @entity65 0.73 (95% CI 0.62-0.85) and for @entity944 .76 (95% CI 0.62-0.93). These findings did not alter after extensive correction for potential confounders, including treatment modality. Importantly, no interaction was found between serum @entity4613 and serum @entity4612 . Baseline serum @entity4612 was not related to non- @entity65 . @entity4612 decreased slightly but statistically significant over time (   -0.011 mmol/L/year, 95% CI -0.017 to -0.009, p = 0.03). In short, serum @entity4612 has a strong, independent association with all-cause mortality, @entity65 and @entity944 in European HD patients. Serum @entity4612 levels decrease slightly over time.

title: Serum XXXX and @entity944 in European Hemodialysis @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death 0', 'sudden death']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular mortality']

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']

answer: @entity1760 :: (MESH:D008274,Chemical) :: ['Magnesium']


abstract: BackgroundThe Hedgehog (Hh) signaling pathway has been implicated in stem cell maintenance and its activation is aberrant in several types of @entity5 including @entity2615 . Protein kinase CK2 affects several cell signaling pathways through the mechanism of phosphorylation.MethodsProtein and mRNA levels of CK2   and @entity8889 were tested by quantitative RT-PCR and immunohistochemistry staining in @entity2615 samples and cell lines. Down-regulated @entity8889 expression and transcriptional activity were demonstrated by RT-PCR, Western blot and luciferase reporter assay.ResultsIn this study, we show that CK2   is over-expressed and a positive regulator of Hegdehog/ @entity8889 signaling in @entity1 @entity3620 . First of all, we found that the mRNA levels of CK2   and @entity8889 were broadly elevated and correlated (n  =  52, r  =  0.401, P  <  0.05), compared with LP9 (a normal mesothelial cell line). We then investigated their expression at the protein level, and found that all the 7 @entity2615 cell lines tested showed positive staining in CK2   and @entity8889 immunohistochemistry. Correlation analysis by Pearson test for CK2   and @entity8889 expression in the 75 @entity5 and the 7 @entity2615 cell lines showed that the two protein expression was significantly correlated (n  =  82, r  =  0.554, P  <  0.01). Furthermore, we demonstrated that @entity8889 expression and transcriptional activity were down-regulated after CK2   was silenced in two @entity2615 cell lines (H28 and H2052). CK2   siRNA also down-regulated the expression of Hh target genes in these cell lines. Moreover, treatment with a small-molecule CK2   inhibitor @entity15440 led to dose-dependent inhibition of @entity8889 expression and transcriptional activity. Conversely, forced over-expression of CK2   resulted in an increase in @entity8889 transcriptional activity in H28 cells.ConclusionsThus, we report for the first time that over-expressed CK2   positively regulate Hh/ @entity8889 signaling in @entity1 @entity2615 .

title: CK2  , over-expressed in XXXX @entity3620 , regulates the Hedgehog signaling pathway in @entity2615 cells.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'mesothelioma tumors']

entities_list: @entity2615 :: ('MESH:D008654', 'Disease') :: ['mesothelioma']

entities_list: @entity3620 :: ('MESH:C562839', 'Disease') :: ['malignant pleural mesothelioma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVE: To determine the hypothesis that genetic variations of the @entity5752 ( @entity5752 ) gene influence risk for the development of @entity295 and @entity881 ( @entity881 ) in @entity1 with @entity130 . BACKGROUND: @entity5752 plays a central role in innate immune response as the first line of defense and directing the microbial-induced activation of the inflammatory host response. Although a total of 112 single nucleotide polymorphisms (SNPs) have been identified so far within the entire @entity5752 gene, only a few SNPs have been studied. METHODS: Nine haplotype tagging SNPs (htSNPs) were selected from 51 SNPs with a minor allele frequency of >= 5% using the HapMap database for the Chinese Han population. Two independent cohorts of @entity130 @entity1 were recruited. The 9 htSNPs were genotyped using pyrosequencing method and analyzed in relation to the risk of development of @entity295 and @entity881 , @entity5752 production, and lipopolysaccharide (LPS)-induced activation of peripheral blood leukocytes. Moreover, the functionality of the @entity23813 polymorphism was assessed by the observation of its effects on the binding and activation of LPS and the @entity5752 - @entity5750 interaction. RESULTS: Among the 9 htSNPs, only the @entity23813 was significantly associated with higher susceptibility to @entity295 and @entity881 in the 2 independent cohorts of @entity130 @entity1 recruited from southwest and eastern China. This SNP was also significantly associated with LPS-induced activation of peripheral blood leukocytes. In addition, the @entity23813 polymorphism could enhance @entity5752 protein activities, showing significant increases in LPS binding to macrophages, LPS-induced cellular activation, and @entity5752 - @entity5750 interaction at the presence of the variant @entity5752 protein. CONCLUSIONS: The @entity23813 polymorphism is a functional SNP and confers host susceptibility to @entity295 and @entity881 in @entity1 with @entity130 .

title: A functional variant of lipopolysaccharide binding protein predisposes to @entity295 and @entity881 in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5752 :: ('3929', 'Gene') :: ['lipopolysaccharide-binding protein', 'LBP', 'Lipopolysaccharide-binding protein']

entities_list: @entity881 :: ('MESH:D009102', 'Disease') :: ['multiple organ dysfunction', 'MOD']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['major trauma']

answer: @entity130 :: (MESH:D014947,Disease) :: ['major trauma']


abstract: We investigated 30 @entity1 with advanced and metastatic @entity0 who underwent @entity416 therapy in our department from July, 2004 to April, 2009. @entity1 ' backgrounds: 35-82 years of age (median, 62 years of age). Performance status (PS): 0 approximately 1 in 21 cases, PS:2 in 7 cases and PS:3 in 2 cases. 63% of @entity1 were positive ER and/or @entity7273 , and 33. 3% were positive @entity1722 . Of these @entity1 , 17 had bone, 15 lymph node, 13 lung, 7 liver, and 4 skin @entity3 . The @entity416 response in these @entity1 was evaluated as follows: partial response (PR) in 9, @entity66 ( @entity168 )in 6, long @entity168 in 4, and progressive disease( @entity1726 )in 11, indicating a response rate(RR)of 30% and a clinical benefit rate (CBR) of 43. 3%. In comparison with after third-line treatment, @entity416 proved more effective as first or second-line treatment. Interestingly, the @entity416 response in @entity1722 negative-expressing @entity1 , especially in HR(+)/ @entity1722 (-)subgroup, was significantly better than that in @entity1722 -over-expressing @entity1 . The soft tissue lesions( @entity5 and @entity3 of skin and lymph nodes)showed a significantly better response to @entity416 treatment than other metastases such as lung, liver and bone. There was a significant difference in the response rate between soft tissue @entity3 (lymph nodes, skin and @entity5 )and other types of @entity3 (lung, liver, and bone). Finally, it was suggested that use of @entity416 in upfront line for @entity1722 -negative expressing cases or soft tissue metastatic cases contributed to the prolongation of time to treatment failure( @entity19246 )and overall survival.

title: [More effective positioning of XXXX for advanced and metastatic @entity0 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity416 :: (MESH:C110904,Chemical) :: ['capecitabine']


abstract: Even as further refinements of anti- @entity2874 continue to emerge, new biologics targeting alternative mechanisms are progressing through clinical development programs and offer the opportunity for categorically new therapeutics in the years ahead. Several of these target regulatory cytokines occupy important nodal positions in the intricate pathways mediating immune and inflammatory injury. A number of agents which antagonize the IL-12/ @entity4452 @entity2270 appear to offer promise. The apparent efficacy of these anti-cytokine agents has served as a stimulus for development of therapeutics that inhibits the signaling pathway common to their action. In addition to the focus of new biologic development on additional components of the cytokine network, other biologics target mechanisms of recruitment of various key cell populations to mucosa involved in @entity29 . Natalizumab is already approved for clinical use and targets alpha4 with proven efficacy in @entity30 . A more specific antibody designated finds alpha4beta7 (also known as MAdCAM) trials has had efficacy in @entity31 and probable efficacy in @entity30 . Efforts continue to exploit increasing understanding of the mechanisms necessary for T cell activation, and most especially co-stimulatory molecules to intervene in immune-related injury. A chimeric protein encompassing @entity4386 and an immunoglobulin tail (abatacept) has yielded promising results. Another mechanistic strategy to intervene with recruitment of key leukocytes to sites of disease activity has focused on members of the chemokine family that appear to be especially critical to the intestinal mucosa. In summary, the expanding knowledge of mechanisms that contribute to the pathogenesis of @entity29 has yielded a wealth of new potential targets and the results of the variety of agents currently being developed offer promise for a rich mix of next-generation biologics.

title: Beyond tumor necrosis factor: next-generation biologic therapy for XXXX .

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'inflammatory bowel diseases']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity29 :: (MESH:D015212,Disease) :: ['inflammatory bowel disease']


abstract: OBJECTIVE: The aim of this study was to investigate the protective effect of physiologic ischemic training of normal skeletal muscle against @entity583 . DESIGN: Thirty-five @entity95 were implanted with water balloon constrictors in the left ventricular branch to cause @entity741 and an electrode near the left sciatic nerve for electric muscle stimulation for physiologic ischemic training. Three groups were randomly selected: the pure @entity63 (PI) group received @entity741 for 2 mins, two times a day, five times a week; the exercise training (ET) group received @entity741 as did the PI group, plus 4 mins of physiologic ischemic training, two times a day, five times a week; and the sham-operated (SO) group was the sedentary controls. After 4 wks of training, the left ventricular branch was occluded to cause @entity1188 . @entity1188 size was measured by magnetic resonance imaging; left ventricular ejection fraction, by echocardiogram; capillary density, by immunohistochemistry; and collateral circulation blood flow, by a microsphere technique. RESULTS: The ET group's @entity1188 size was significantly smaller than that of the PI group (P < 0.01) and the SO group (P < 0.01). Change in left ventricular ejection fraction in the ET group was significantly lower than in the SO group (P < 0.01), and capillary density in the ET group was significantly higher than in the PI group (P< 0.01) and the SO group (P < 0.01). Collateral circulation blood flow in the ET group was significantly higher than in the PI group (P < 0.01) and the SO group (P< 0.01). Capillary density was significantly correlated with endpoint collateral circulation blood flow (r = 0.91, P = 0.000), @entity1188 size (r = -0.91, P = 0.000), and change in left ventricular ejection fraction (r = -0.94, P = 0.000). CONCLUSIONS: Physiologic ischemic training of skeletal muscle may induce collateral circulation development in the myocardium, thus decreasing @entity1188 size when @entity1188 occurs.

title: Effect of physiologic ischemic training on protection of @entity583 in XXXX .

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['Infarct', 'infarct', 'infarction']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['myocardial ischemia']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

answer: @entity95 :: (9986,Species) :: ['rabbits']


abstract: BACKGROUND: Standard treatment of @entity483 ( @entity483 ) is based on topical glucocorticosteroids or calcineurin inhibitors to treat flares combined with moisturizer treatment to alleviate dry skin symptoms. @entity1 with @entity483 have an abnormal skin barrier function, and strategies for reducing the risks for @entity484 would be to repair the barrier or prevent @entity409 . OBJECTIVES: The objective of this study was to explore the time to relapse of @entity484 during a 26-week maintenance treatment with a @entity1133 containing moisturizer compared to no treatment (neither medical nor non-medicated preparations) after successful clearing of @entity75 . The moisturizer has previously been shown to improve skin barrier function. METHODS: @entity1 applied @entity17834 (0.1%) on @entity75 during a 3-week period. Those with @entity484 entered a 26-week maintenance phase, applying the moisturizer or left the previously affected area untreated. Upon @entity484 relapse, @entity1 were instructed to contact the clinic and to have the relapse confirmed by the investigator. RESULTS: Fifty-five @entity1 entered the study and 44 @entity1 were included in the maintenance phase (22 using moisturizer twice daily and 22 using no treatment). Median time to relapse for @entity1 treated with moisturizer was > 180 days (duration of the study) compared with 30 days for the no-treatment group. Sixty-eight per cent of the @entity1 treated with the moisturizer and 32% of the untreated @entity1 remained free from @entity484 during the observation period. CONCLUSIONS: Maintenance treatment with a barrier-improving @entity1133 moisturizer on previous eczematous areas reduced the risk of relapse to approximately one third of that of no treatment.

title: Treatment with a barrier-strengthening moisturizing cream delays relapse of XXXX : a prospective and randomized controlled clinical trial.

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['atopic dermatitis', 'AD']

entities_list: @entity17834 :: ('CHEBI:31277', 'Chemical') :: ['betamethasone valerate']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['eczematous lesions', 'atopic lesions']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['barrier dysfunction']

entities_list: @entity484 :: ('MESH:D004485', 'Disease') :: ['eczema', 'cleared eczema']

answer: @entity483 :: (MESH:D003876,Disease) :: ['atopic dermatitis']


abstract: OBJECTIVE: To find the control degree of a population of @entity101 @entity1 . To evaluate the cost effectiveness of health services. SETTING: EAP Salvador Pau. Valencia (Spain). @entity1 : 200 @entity1 diagnosed of @entity101 included in the health center file. MEASUREMENTS AND RESULTS: Items studied were age, sex, diagnosis and program inclusion year, number of visits, other explorations and its cost, @entity823 and TAD, drugs and its cost, personnel cost. We established different well control levels and we obtained the cost of each of them. Twenty six point five per cent of @entity1 had TA values below 140/90 mmHg; Sixty four point five per cent had values below 160/90 mmHg. And sixty six point nine had values below 90 mmHg. Monthly medium cost per @entity1 was 3242 pts. Monthly medium cost per @entity1 well controlled was 12234 pts. CONCLUSIONS: Only a third of our @entity1 are well controlled according the current standards. Efficiency decreases noteworthy when control levels are lower.

title: [Description of costs and effectiveness of a XXXX control program in primary care].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: UNASSIGNED: Interferon-lambda (IFN-  ) has potent antiviral effects against multiple enteric viral pathogens, including norovirus and rotavirus, in both preventing and curing @entity281 . Because the intestine includes a diverse array of cell types, however, the cell(s) upon which IFN-   acts to exert its antiviral effects are unclear. Here, we sought to identify IFN-   responsive cells by generation of @entity19 with lineage-specific deletion of the receptor for IFN-  , @entity18166 We found that expression of @entity18166 on intestinal epithelial cells (IECs) in the small intestine and colon is required for enteric IFN-   antiviral activity. IEC @entity18166 expression also determines the efficacy of IFN-   in resolving persistent @entity19 norovirus (MNoV) @entity281 and regulates fecal shedding and viral titers in tissue. Expression of @entity18166 by IECs is thus necessary for the response to both endogenous and exogenous IFN-  . We further demonstrate that IEC @entity18166 expression is required for the sterilizing innate immune effects of IFN-   by extending these findings in @entity5350 -deficient @entity19 . Finally, we assessed whether our findings pertained to multiple viral pathogens by infecting @entity19 specifically lacking IEC @entity18166 expression with reovirus. These @entity19 phenocopied @entity18166 -null animals, exhibiting increased intestinal tissue titers and enhanced reovirus fecal shedding. IECs are thus the critical cell type responding to IFN-   to control multiple enteric viruses. This is the first genetic evidence that supports an essential role for IECs in IFN-  -mediated control of enteric @entity1800 , and these findings thus provide insight into the mechanism of IFN-  -mediated antiviral activity. IMPORTANCE: @entity1 noroviruses (HNoVs) are the leading cause of @entity1902 worldwide. Type III interferons (IFN-  ) control enteric @entity1800 in the gut, and have been shown to cure @entity19 norovirus, a small animal model for HNoVs. Using a genetic approach with conditional knock-out @entity19 , we identified intestinal epithelial cells (IECs) as the dominant IFN-  -responsive cells in control of enteric @entity778 in vivo Upon @entity19 norovirus or reovirus @entity281 , @entity18166 depletion in IECs largely recapitulated the phenotype seen in @entity18166 (-/-) @entity19 of higher intestinal tissue viral titers and increased viral shedding in the stool. Moreover, IFN-  -mediated sterilizing immunity against @entity19 norovirus requires the capacity of IECs to respond to IFN-  . These findings clarify the mechanism of action of this cytokine, and emphasize the therapeutic potential of IFN-   for treating mucosal @entity1800 .

title: Expression of XXXX on intestinal epithelial cells is critical to the antiviral effects of IFN-lambda against norovirus and reovirus.

entities_list: @entity778 :: ('MESH:D015658', 'Disease') :: ['virus infection']

entities_list: @entity1902 :: ('MESH:D005759', 'Disease') :: ['epidemic gastroenteritis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infections', 'viral infection']

answer: @entity18166 :: (242700(Tax:10090),Gene) :: ['Ifnlr1']


abstract: To investigate the utilization of nutrients by @entity5 in @entity1 , the balances of energy-yielding substrates and @entity1522 across @entity694 were assessed in 17 @entity1 during surgery. Blood samples were taken from an artery and the main @entity5 -draining vein, which was also used for determining @entity5 blood flow (direct venous outflow technique). Additionally, the substrate exchange by peripheral tissues was studied (femoral arteriovenous differences, @entity432 plethysmography). Mean blood flow was greater in the @entity189 than in the leg tissues (43.2 versus 2.5 ml/100 ml/min; P < 0.001). There was a negative correlation between @entity5 blood flow and @entity5 weight (r = -0.87; P < 0.001). @entity413 net uptake and @entity880 release by the @entity5 exceeded the peripheral exchange rates 30- and 43-fold, respectively (mean values different at P < 0.001). The molar ratio of lactate output to @entity413 consumption was 0.78 in the @entity5 and 0.48 in the leg tissues (P < 0.05). Regarding free @entity844 and @entity6178 body balances, no significant @entity5 -periphery differences were noted. The @entity189 utilized branched chain @entity1522 and @entity563 , while @entity493 and, in particular, @entity3265 were released in large amounts. Net @entity1160 retention was not consistently observed. It is concluded that the energy metabolism of @entity1 @entity694 relies predominantly on @entity413 , with fat-derived calories making no appreciable contribution. The impaired nutritive perfusion of @entity5 appears to favor glycolysis and to limit both @entity413 oxidation and glutaminolysis. The present study has shown that the procedure chosen for the assessment of trans- @entity5 substrate flux rates is a workable and valid model for analyzing metabolic balances across @entity1 @entity694 in vivo.

title: Substrate XXXX in @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human', 'patients']

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity1160 :: ('CHEBI:28300', 'Chemical') :: ['glutamine']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies', 'tumor', 'tumors', 'malignant tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['venous occlusion']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic cancers', 'colonic carcinomas']

entities_list: @entity493 :: ('CHEBI:16449', 'Chemical') :: ['alanine']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['Glucose', 'glucose']

answer: @entity694 :: (MESH:D003110,Disease) :: ['balances across colonic carcinomas']


abstract: Currently no standard treatment for @entity1 with @entity157 ( @entity157 ), and available literature assessing @entity2390 's treatment effect on @entity157 reports discordant results. The primary purpose of this study was to evaluate the effect of @entity2390 therapy on @entity1 survival. The secondary endpoints were to assess @entity5 response, quality of life and adverse effects. PUBMED, MEDLINE, OVID and SPRINGER databases were searched through January 2009. Randomized controlled trials that compared @entity2390 treatment with placebo or no treatment were selected. Finally, four randomized controlled trials (three of which were high quality trials) published in 1998 or later with a total of 373 @entity1 were included in this review. Because a significant clinical heterogeneity existed between the included trials, making meta-analysis inappropriate; only a narrative systematic review was performed. Of the three high-quality trials, only one(126 @entity1 ) reported @entity2390 could improve survival and quality of life of @entity157 @entity1 , whereas the other two(189 @entity1 ) suggested @entity2390 did not have survival benefit in @entity157 ; moreover, none of the three trials indicated that @entity2390 has significant beneficial effect on @entity5 regression or decrease of @entity5 mass. Nonetheless, serious adverse effects were not reported in these included trials. In this review, results from included randomized controlled trials demonstrated no clear benefit of @entity2390 therapy in advanced @entity157 @entity1 . In order to detect a realistic treatment advantage, further larger well-designed multicenter randomized trials will have to be conducted.

title: XXXX therapy for @entity157 : a systematic review of the evidence from randomized controlled trials.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'advanced hepatocellular carcinoma']

entities_list: @entity2390 :: ('MESH:D015282', 'Chemical') :: ['octreotide']

answer: @entity2390 :: (MESH:D015282,Chemical) :: ['Octreotide']


abstract: OBJECTIVES: The objective was to examine the effectiveness of corticosteroid treatment for the relief of @entity158 associated with @entity697 potentially caused by group A beta-hemolytic Streptococcus (GABHS). METHODS: This was a systematic review of the literature. Data sources used were electronic databases (Cochrane Library, MEDLINE, EMBASE, Biosis Previews, Scopus, and Web of Science), controlled trial registration websites, conference proceedings, study references, experts in the field, and correspondence with authors. Selection criteria consisted of randomized controlled trials (RCTs) in which @entity288 , alone or in combination with antibiotics, were compared to placebo or any other standard therapy for treatment of @entity697 in adult @entity1 , pediatric @entity1 , or both. Two reviewers independently assessed for relevance, inclusion, and study quality. @entity353 ( @entity353 ) were calculated and are reported with corresponding 95% confidence intervals (CIs). RESULTS: From 272 potentially relevant citations, 10 studies met the inclusion criteria. When compared to placebo, @entity288 reduced the time to clinically meaningful @entity158 relief (WMD = -4.54 hours; 95% CI = -7.19 to -1.89); however, they provided only a small reduction in @entity158 scores at 24 hours (WMD = -0.90 on a 0-10 visual analog scale; 95% CI = -1.5 to -0.3). Heterogeneity among pooled studies was identified for both outcomes (I(2) = 81 and 74%, respectively); however, the GABHS-positive subgroup receiving @entity228 treatment did have a significant mean reduction in time to clinically meaningful @entity158 relief of 5.22 hours (95% CI = -7.02 to -3.42; I(2) = 0%). Short-term side effect profiles between @entity288 and placebo groups were similar. CONCLUSIONS: @entity228 administration for @entity697 was associated with a relatively small effect in time to clinically meaningful @entity158 relief (4.5-hour reduction) and in @entity158 relief at 24 hours (0.9-point reduction), with significant heterogeneity in the pooled results. Decision-making should be individualized to determine the risks and benefits; however, @entity288 should not be used as routine treatment for @entity697 .

title: Effectiveness of corticosteroid treatment in XXXX : a systematic review of the literature.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute pharyngitis']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['WMDs', 'Weighted mean differences']

entities_list: @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid', 'Corticosteroid']

entities_list: @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']

answer: @entity697 :: (MESH:D000208,Disease) :: ['acute pharyngitis']


abstract: @entity2335 / @entity2336 ( @entity2337 ) is a chronic syndrome of unknown etiology that presents with @entity2336 , urinary frequency, and urgency. The lack of specific biomarkers and a poor understanding of underlying molecular mechanisms present challenges for disease diagnosis and therapy. The goals of this study were to identify noninvasive biomarker candidates for @entity2337 from urine specimens and to potentially gain new insight into disease mechanisms using a nuclear magnetic resonance (NMR)-based global metabolomics analysis of urine from female @entity2337 @entity1 and controls. Principal component analysis (PCA) suggested that the urinary metabolome of @entity2337 and controls was clearly different, with 140 NMR peaks significantly altered in @entity2337 @entity1 (FDR < 0.05) compared to that in controls. On the basis of strong correlation scores, fifteen metabolite peaks were nominated as the strongest signature of @entity2337 . Among those signals that were higher in the @entity2337 group, three peaks were annotated as @entity6114 , the @entity158 -related neuromodulator. Two peaks were annotated as @entity15706 . Levels of @entity6114 and @entity15706 were significantly elevated in urine specimens of @entity2337 subjects. An independent analysis using mass spectrometry also showed significantly increased levels of @entity6114 and @entity15706 in @entity2337 @entity1 compared to controls. Functional studies showed that @entity15706 , but not @entity6114 , retarded growth of normal bladder epithelial cells. These preliminary findings suggest that analysis of urine metabolites has promise in biomarker development in the context of @entity2337 .

title: Urinary metabolite profiling combined with computational analysis predicts XXXX -associated candidate biomarkers.

entities_list: @entity15706 :: ('MESH:C029743', 'Chemical') :: ['2-oxoglutarate']

entities_list: @entity2336 :: ('MESH:D018856', 'Disease') :: ['painful bladder syndrome', 'bladder pain']

entities_list: @entity2335 :: ('MESH:D003556', 'Disease') :: ['Interstitial cystitis']

entities_list: @entity6114 :: ('MESH:D014439', 'Chemical') :: ['tyramine']

answer: @entity2335 :: (MESH:D003556,Disease) :: ['interstitial cystitis']


abstract: CONTEXT: There is scarce knowledge about the growth hormone (GH) insulin-like growth factor-1 ( @entity442 ) axis in @entity1 _ adolescents with @entity29 ( @entity29 ) and @entity851 . OBJECTIVE: To describe the pattern of GH and @entity442 secretion in @entity1 _ adolescents with @entity29 . DESIGN: A retrospective review of 28 @entity1 (23 M) of @entity29 (25 @entity30 and three @entity31 ) and @entity851 who had investigation of the GH/ @entity442 axis. Height velocity (HV) and serum @entity442 were converted to standard deviation score ( @entity214 ); to account for delayed @entity1175 in @entity1 over 11 years and @entity1 over 12 years, HV and serum @entity442 @entity214 were adjusted for bone age. RESULTS: Median (range) age and Ht @entity214 at the time of endocrine evaluation was 14.3 years (7.7,17.0) and -2.0(-3.6,-0.9), respectively. Median HVSDS over the prior 12 months was -2.2(-7.7,2.8). Median peak serum GH on insulin tolerance test (ITT) was 5.8 mcg/l (1.3, 24.0), and median serum @entity442 @entity214 was -0.9(-3.1, 0.1). Five of 28 (18%) had a peak serum GH of >12 mcg/l. Overall, four had biochemical evidence of functional @entity2338 (peak GH < 3 mcg/l and @entity442 @entity214 < 0) and 11 @entity1 had biochemical evidence suggesting GH resistance (peak GH > 6 mcg/l and @entity442 @entity214 < 0). However, only one @entity1 had a peak serum GH > 6 mcg/l and a very low @entity442 @entity214 of <-2.0. There was a negative association between peak serum GH and Ht @entity214 (r = -0.49, P = 0.008), but there was no association with HV and there was no association between @entity442 @entity214 and Ht or HV @entity214 . @entity442 @entity214 showed a negative association with erythrocyte sedimentation rate (r = -0.41, P = 0.04). CONCLUSION: @entity851 in @entity1 and adolescents with @entity29 is commonly associated with a range of biochemical @entity851 to GH resistance. In these @entity1 , poor relationship between systemic markers of growth and height velocity point to an important role of growth factors at the target organ level in modulating growth in @entity1 with @entity29 . The value of assessing the GH/ @entity442 axis and whether it predicts subsequent response to growth-promoting therapy requires further exploration.

title: The growth hormone insulin-like growth factor 1 axis in XXXX and adolescents with @entity29 and @entity851 .

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children', 'patients', 'girls', 'boys']

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['GH deficiency']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['abnormalities ranging from functional GH deficiency', 'Growth retardation', 'growth retardation']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['Ulcerative Colitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's Disease"]

answer: @entity1 :: (9606,Species) :: ['children']


abstract: Many lines of evidence have shown that Chinese medicine contains many chemical compounds with anticancer effects. Therefore, we tested whether the active ingredients of blister beetles have a therapeutic effect on @entity157 . The aim of this study was to investigate the inhibitive effects of norcantharidin which is extracted from blister beetles on @entity1 @entity157 cells HepG2 in  vitro and its anticancer mechanism.MTT assay, agarose gel electrophoresis and flow cytometry were used to evaluate HepG2 cells proliferation and apoptosis. The role of caspase activities were assayed using caspase apoptosis detection kit. Western blot analysis was used to evaluate the level of @entity588 / @entity589 expression. Our results indicate that norcantharidin inhibited HepG2 cell growth in a time- and dose-dependent manner by MTT assay. HepG2 cells treated with norcantharidin showed typical characteristics of apoptosis including the DNA fragmentation. The activities of @entity9189 were up-regulated after norcantharidin treatment. By western blot analysis, we found the level of @entity588 were down-regulated, whereas, the level of @entity588 Up-regulated.so we suggest that up-regulation of mitochondrial @entity589 expression and down-regulation of @entity588 expression participated in the apoptosis induced by NCTD. These results suggest that norcantharidin triggers apoptosis in hepato @entity5 cell lines via the activation of the caspses, mitochondrial pathways, and that this agent may be useful for developing new therapeutic regimens for the treatment of @entity14 .

title: The anti-proliferative effects of norcantharidin on XXXX HepG2 cells in cell culture.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal carcinoma']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatoma']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: A 37-year-old @entity1 was examined because of temporary @entity294 . On CT scan, there was an abnormality of the liver. MRI showed a @entity5 that was suspicious for @entity652 . Biopsy confirmed the diagnosis of @entity8055 . The @entity1 then discontinued the use of oral contraceptives. The @entity5 regressed and was resected after two years. A 22-year-old @entity1 presented with @entity490 . A @entity5 was found in the upper right quadrant of the abdomen. In the laboratory, liver function tests were abnormal. Ultrasound and a CT scan of the liver showed an @entity652 . After withdrawal of oral contraceptives, abdominal complaints lessened, but no regression of the @entity5 was detected. Surgical resection was uncomplicated. @entity8055 is a rare, @entity5 , most often seen in young healthy @entity1 . Its incidence is rising due to the prolonged use of oral contraceptives. Not rarely, @entity5 are incidental findings on echography. If symptomatic, the presentation usually consists of vague abdominal complaints. @entity1409 and @entity528 have been reported for @entity652 . A reliable diagnosis is mandatory for the decision whether to apply surgery or continue observation. Radiological investigations play a key role in the detection and diagnosis of @entity8055 . Due to the risk of @entity548 and @entity528 , elective surgical resection is indicated in symptomatic @entity652 , asymptomatic @entity652 larger than 5 cm in diameter, and smaller @entity652 without regression after discontinuation of oral contraceptives.

title: [ XXXX , a @entity5 particularly seen in mostly young @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'woman', 'patient']

entities_list: @entity8055 :: ('MESH:D018248', 'Disease') :: ['Hepatocellular adenoma', 'hepatocellular adenoma']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity1409 :: ('MESH:D012422', 'Disease') :: ['Spontaneous rupture']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['benign tumour of the liver', 'benign liver tumours', 'tumour']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas', 'adenoma']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['malignant degeneration']

answer: @entity8055 :: (MESH:D018248,Disease) :: ['Hepatocellular adenoma']


abstract: A conserved motif, GXXX(D/E)(R/K)XG(R/K)(R/K), has been identified among a large group of evolutionarily related membrane proteins involved in the transport of small molecules across the membrane. To determine the importance of this motif within the @entity1132 permease of @entity526 , a total of 28 site-directed mutations at the conserved first, fifth, sixth, eighth, ninth, and tenth positions were analyzed. A dramatic inhibition of activity was observed with all bulky mutations at the first-position @entity2228 . Based on these results, together with sequence comparisons within the superfamily, it seems likely that small side chain volume (and possibly high beta-turn propensity) may be structurally important at this position. The acidic residue at the fifth position was also found to be very important for transport activity and even a conservative @entity2227 at this location exhibited marginal transport activity. In contrast, many substitutions at the eighth-position @entity2228 , even those with a high side chain volume and/or low beta-turn propensity, still retained high levels of transport activity. Similarly, none of the basic residues within the motif were essential for transport activity when replaced individually by nonbasic residues. However, certain substitutions at the basic residue sites as well as the eighth-position @entity2228 were observed to have moderately reduced levels of active transport of @entity1132 . Taken together, the results of this study confirm the importance of the conserved loop 2/3 motif in transport function. It is suggested that this motif may be important in promoting global conformational changes within the permease.

title: The conserved motif, GXXX(D/E)(R/K)XG[X](R/K)(R/K), in hydrophilic loop 2/3 of the XXXX permease.

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli']

entities_list: @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

answer: @entity1132 :: (MESH:D007785,Chemical) :: ['lactose']


abstract: The aim of the study was to investigate the effects of hypovitaminosis D on @entity158 , quality of life (QoL) and nerve conduction studies (NCSs) in @entity1 with chronic @entity158 (CWP). We randomly selected 83 female @entity1 with CWP according to their @entity560 levels in this cross-sectional study. @entity1 were divided into two groups as sufficient @entity560 level (above 20  ng/ml) and deficient @entity560 level (below 20  ng/ml, hypovitaminosis D). Various @entity158 scales and Nottingham Health Profile (NHP) were used. NCSs were also done. In @entity1 with hypovitaminosis D, there were significantly @entity158 scores for all scales (p value range 0.002-0.027). The subscale and total NHP scores were significantly higher in hypovitaminosis D group (p  =  0.048-0.001) except social isolation subscale (p  =  0.553). @entity560 levels were in negative correlation with right and left median and/or ulnar motor nerve amplitudes, left tibial motor amplitude. This study confirm that hypovitaminosis D is related with @entity158 intensity and lower QoL scores in @entity1 with CWP when compared with control group. Additionally, we identified for the first time that there were negative correlations between @entity560 levels and some findings of NCSs.

title: Hypovitaminosis D in @entity158 : its effect on XXXX perception, quality of life and nerve conduction studies.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['higher pain', 'pain', 'widespread pain']

entities_list: @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D', 'Vitamin D']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: BACKGROUND: @entity1 with abusive @entity542 (AHT) have diffuse @entity75 with potentially fatal @entity4 . The pathogenesis of the @entity75 remains unclear. We hypothesize that @entity75 in AHT is due to @entity63 with @entity2806 ( @entity2806 ) rather than primary @entity131 ( @entity131 ) with traumatic @entity21 (tDAI). METHODS: We studied brain tissue of AHT victims. Primary outcome measure was the presence of primary traumatic versus @entity2806 . The diagnosis of tDAI followed a standardized semiquantitative diagnostic approach yielding a 4-tiered grading scheme (definite, possible, improbable, and none). In addition, results of quantitative immunohistochemical analysis in a subgroup of AHT victims with instant @entity204 were compared with matched @entity6884 controls. RESULTS: In our cohort of 50 AHT victims, none had definite tDAI (no tDAI in 30, tDAI possible in 2, and tDAI improbable in 18). Instead, all AHT victims showed morphological findings indicative of @entity2806 . Furthermore, the subgroup with instant @entity204 showed significantly higher counts of damaged axons with accumulation of @entity477 ( @entity477 ) in the brainstem adjacent to the central pattern generator of respiratory activity (CPG) (odds ratio adjusted for age, sex, brain weight, and @entity477 -count in other regions   =   3.1; 95  % confidence interval   =   1.2 to 7.7; p   =   0.015). CONCLUSIONS: AHT victims in our cohort do not have diffuse @entity131 or tDAI. Instead, our findings indicate that the @entity75 in AHT is the due to @entity63 probably as the result of @entity1576 due to local damage to parts of the CPG in the brainstem.

title: XXXX and @entity204 in @entity1 with abusive @entity542 is due to @entity63 following local @entity131 .

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['hypoxic-ischemic brain injury', 'hypoxic-ischemic encephalopathy', 'HIE']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['hypoxic-ischemic injury']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy', 'brain damage']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['brain swelling']

entities_list: @entity542 :: ('MESH:D006259', 'Disease') :: ['head trauma']

entities_list: @entity477 :: ('351', 'Gene') :: ['amyloid precursor protein', 'APP']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory arrest']

entities_list: @entity21 :: ('MESH:D001480', 'Disease') :: ['diffuse axonal injury']

answer: @entity75 :: (MESH:D001927,Disease) :: ['Encephalopathy']